A detailed history of Nisa Investment Advisors, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 794 shares of RCUS stock, worth $12,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares
794
Previous 739 7.44%
Holding current value
$12,156
Previous $13,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$14.59 - $18.48 $802 - $1,016
55 Added 7.44%
794 $12,000
Q1 2024

May 01, 2024

BUY
$14.83 - $20.18 $1,364 - $1,856
92 Added 14.22%
739 $13,000
Q4 2023

Jan 25, 2024

SELL
$13.43 - $19.63 $537 - $785
-40 Reduced 5.82%
647 $12,000
Q3 2023

Nov 02, 2023

BUY
$17.62 - $23.54 $176 - $235
10 Added 1.48%
687 $12,000
Q2 2023

Aug 11, 2023

BUY
$16.97 - $22.03 $5,684 - $7,380
335 Added 97.95%
677 $13,000
Q1 2023

May 02, 2023

SELL
$15.96 - $23.15 $24,530 - $35,581
-1,537 Reduced 81.8%
342 $6,000
Q4 2022

Feb 02, 2023

SELL
$19.7 - $35.71 $492 - $892
-25 Reduced 1.31%
1,879 $39,000
Q3 2022

Nov 07, 2022

BUY
$23.23 - $30.07 $859 - $1,112
37 Added 1.98%
1,904 $49,000
Q2 2022

Aug 03, 2022

SELL
$17.23 - $37.73 $913 - $1,999
-53 Reduced 2.76%
1,867 $47,000
Q1 2022

Apr 29, 2022

SELL
$28.92 - $41.83 $5,205 - $7,529
-180 Reduced 8.57%
1,920 $61,000
Q4 2021

Feb 03, 2022

SELL
$31.38 - $48.47 $10,983 - $16,964
-350 Reduced 14.29%
2,100 $65,000
Q4 2020

Jan 25, 2021

BUY
$17.0 - $32.36 $41,650 - $79,282
2,450 New
2,450 $64,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.1B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.